Susan E Prockop, Aisha N Hasan, Ekaterina Doubrovina, Parastoo B Dahi, M Irene Rodriguez-Sanchez, Michael Curry, Audrey Mauguen, Genovefa A Papanicolaou, Yiqi Su, JinJuan Yao, Maria E Arcila, Farid Boulad, Hugo Castro-Malaspina, Christina Cho, Kevin J Curran, Sergio Giralt, Nancy A Kernan, Guenther Koehne, Ann Jakubowski, Esperanza Papadopoulos, Miguel-Angel Perales, Ioannis Politikos, Keith J Price, Annamalai Selvakumar, Craig S Sauter, Roni Tamari, Teresa Vizconde, James W Young, Richard J O'Reilly
BACKGROUND: Refractory CMV viremia and disease are associated with significant morbidity and mortality in recipients of hematopoietic stem cell transplant (HCT). METHODS: In Phase I/II trials, we treated 67 subjects for CMV viremia or disease arising after allogeneic hematopoietic cell transplant with adoptive transfer of banked off-the-shelf, 3rd party, CMVpp65-sensitized T cells (CMVpp65-VSTs). All were evaluable for toxicity and 59 for response. Evaluable subjects had CMV disease or persisting viremia that had failed at least two weeks of induction therapy with a median of 3 antiviral drugs; 84...
March 23, 2023: Journal of Clinical Investigation